ACE cohort | Heidelberg/Mannheim cohort | P value of difference | |
---|---|---|---|
MCI patients (N) | 142 | 40 | |
Metabolomics profiling tissue | CSF and plasma | CSF | |
Age (SD) blood collection, years | 71.94 (7.74) | 68.85 (8.50) | 0.042 |
Female (%) | 74 (52%) | 22 (55%) | 0.747 |
Body mass index (SD) | 26.46 (3.74) | 25.85 (3.61) | 0.353 |
Lipid-lowering medication user (%) | 63 (44%) | 11 (27%) | 0.055 |
Amyloid-beta 42 in pg/mL (SD) | 791.59 (337.36) | 690.84 (397.13) | 0.151 |
P-Tau in pg/mL (SD) | 71.37 (37.30) | 63.17 (29.96) | 0.153 |
Total tau in pg/mL (SD) | 478.82 (253.45) | 380.95 (326.97) | 0.124 |
MMSE | 24.93 (4.07) | 26.55 (2.51) | 2.67 × 10−3 |
CDR | 0.50 (0.06) | 0.55 (0.15) | 0.047 |
APOE genotype N (%) | |||
APOE 44/34/24 | 50 (35%) | 18 (45%) | |
APOE 33 | 81 (57%) | 18 (45%) | |
APOE 22/23 | 11 (8%) | 4 (10%) |